PURPOSE: : Interleukin-6 (IL-6) has an important role during prostate cancer progression and IL-6 levels in the serum of patients with hormone refractory and metastatic prostate cancer are significantly increased compared with those in patients with hormone sensitive and localized prostate cancer. The G>C polymorphism at position -174 in the promoter of the IL-6 gene has been associated with differences in IL-6 transcription in vitro and IL-6 protein levels in vivo. We determined the association of IL-6 polymorphism with prostate cancer progression. MATERIALS AND METHODS: : We examined the association of IL-6 polymorphism with the risk of advanced disease in 95 patients with different stages of prostate cancer using the tetra-primer polymerase chain reaction genotyping method. RESULTS: : We found that the -174G>C genotype of IL-6 gene was associated with an overall increased risk of advanced prostate cancer. A strong association between this genotype and Gleason score was observed at the -174G>C locus of the IL-6 gene (p <0.001). The distribution of this genotype was also significantly different between stages T3-T4 and T1-T2 tumors (p <0.001). In addition, the IL-6 genotype was linked with vascular invasion (p = 0.024), seminal vesicle involvement (p = 0.006) and capsular invasion (p <0.001). Furthermore, the -174G>C genotype of the IL-6 gene was significantly associated with increased serum prostate specific antigen (p = 0.004) and with recurrent prostate cancer compared with GG homozygotes (p = 0.027). CONCLUSIONS: : These data demonstrate a strong association of the -174G>C polymorphism of the IL-6 gene with the aggressiveness and recurrence of prostate cancer, suggesting that genetic predisposition of genetic differences in the human IL-6 gene could be linked to the risk of recurrent prostate cancer.
PURPOSE: : Interleukin-6 (IL-6) has an important role during prostate cancer progression and IL-6 levels in the serum of patients with hormone refractory and metastatic prostate cancer are significantly increased compared with those in patients with hormone sensitive and localized prostate cancer. The G>C polymorphism at position -174 in the promoter of the IL-6 gene has been associated with differences in IL-6 transcription in vitro and IL-6 protein levels in vivo. We determined the association of IL-6 polymorphism with prostate cancer progression. MATERIALS AND METHODS: : We examined the association of IL-6 polymorphism with the risk of advanced disease in 95 patients with different stages of prostate cancer using the tetra-primer polymerase chain reaction genotyping method. RESULTS: : We found that the -174G>C genotype of IL-6 gene was associated with an overall increased risk of advanced prostate cancer. A strong association between this genotype and Gleason score was observed at the -174G>C locus of the IL-6 gene (p <0.001). The distribution of this genotype was also significantly different between stages T3-T4 and T1-T2 tumors (p <0.001). In addition, the IL-6 genotype was linked with vascular invasion (p = 0.024), seminal vesicle involvement (p = 0.006) and capsular invasion (p <0.001). Furthermore, the -174G>C genotype of the IL-6 gene was significantly associated with increased serum prostate specific antigen (p = 0.004) and with recurrent prostate cancer compared with GG homozygotes (p = 0.027). CONCLUSIONS: : These data demonstrate a strong association of the -174G>C polymorphism of the IL-6 gene with the aggressiveness and recurrence of prostate cancer, suggesting that genetic predisposition of genetic differences in the humanIL-6 gene could be linked to the risk of recurrent prostate cancer.
Authors: Brandon L Pierce; Mary L Biggs; Marvalyn DeCambre; Alexander P Reiner; Christopher Li; Annette Fitzpatrick; Christopher S Carlson; Janet L Stanford; Melissa A Austin Journal: Cancer Causes Control Date: 2009-03-08 Impact factor: 2.506
Authors: Danyelle A Winchester; Cathee Till; Phyllis J Goodman; Catherine M Tangen; Regina M Santella; Teresa L Johnson-Pais; Robin J Leach; Jianfeng Xu; S Lilly Zheng; Ian M Thompson; M Scott Lucia; Scott M Lippmann; Howard L Parnes; Paul J Dluzniewski; William B Isaacs; Angelo M De Marzo; Charles G Drake; Elizabeth A Platz Journal: Prostate Date: 2015-06-05 Impact factor: 4.104
Authors: Jennifer Rider Stark; Haojie Li; Peter Kraft; Tobias Kurth; Edward L Giovannucci; Meir J Stampfer; Jing Ma; Lorelei A Mucci Journal: Int J Cancer Date: 2009-06-01 Impact factor: 7.396
Authors: J F Magalhães; A J Cortinhas; C M Albuquerque; C S Baptista; R Ribeiro; Carlos Viegas; Augusto Matos; João Machado; Maria A Pires; Henrique Guedes-Pinto; A Martins-Bessa; J C Leitão; E Bastos Journal: Mol Biol Rep Date: 2012-10-17 Impact factor: 2.316